Metrika to submit POC osteoporosis analyzer 510(k) by year end under deal with Ostex.
This article was originally published in The Gray Sheet
Executive Summary
METRIKA LABS DIRECT RESPONSE POC OSTEOPOROSIS TEST 510(k) SUBMISSION is planned for late 1997, the Sunnyvale, California firm says. The one-step point-of-care test is being developed by Metrika under an agreement with Ostex, and detects the cross-linked N-Terminal Telopeptides (NTx) marker owned by Ostex. Ostex will market Direct Response in the U.S. upon clearance by FDA.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.